key: cord-0750859-1g0zvo7g authors: Zhang, Guo-Ning; Zhao, Jianyuan; Li, Quanjie; Wang, Minghua; Zhu, Mei; Wang, Juxian; Cen, Shan; Wang, Yucheng title: Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors date: 2021-06-10 journal: Eur J Med Chem DOI: 10.1016/j.ejmech.2021.113622 sha: 3b81ef4fa90d9cefcc444d736aec967b2a4eb6b6 doc_id: 750859 cord_uid: 1g0zvo7g The emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the global pandemic coronavirus disease (COVID-19), but no specific antiviral drug has been proven effective for controlling this pandemic to date. In this study, several 2-((indol-3-yl)thio)-N-benzyl-acetamides were identified as SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitors. After a two-round optimization, a new series of 2-((indol-3-yl)thio)-N-benzyl-acetamides was designed, synthesized, and evaluated for SARS-CoV-2 RdRp inhibitory effect. Compounds 6b2, 6b5, 6c9, 6d2, and 6d5 were identified as potent inhibitors with IC(50) values of 3.35 ± 0.21 μM, 4.55 ± 0.2 μM, 1.65 ± 0.05 μM, 3.76 ± 0.79 μM, and 1.11 ± 0.05 μM, respectively; the IC(50) of remdesivir (control) was measured as 1.19 ± 0.36 μM. All of the compounds inhibited RNA synthesis by SARS-CoV-2 RdRp. The most potent compound 6d5, which showed a stronger inhibitory activity against the human coronavirus HCoV-OC43 than remdesivir, is a promising candidate for further investigation. Humans are currently affected by the coronavirus disease (COVID-19) pandemic, caused by the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in ~160 million infections and more than 3.3 million deaths worldwide (until May 13, 2021) [1] . To date, no specific antiviral drug has been approved to treat the infection caused by this coronavirus. Furthermore, the interim results of the largest clinical trial of anti-COVID-19 drugs to date show that the four most promising candidate therapies, namely remdesivir [2] [3] [4] , hydroxychloroquine [5] , lopinavir/ritonavir [6] , and interferon-β1a [7] , have little effect on the 28-day mortality or hospitalization course of hospitalized patients. Although vaccines are officially approved for the prevention of COVID-19 and massive vaccination has begun in many countries, infections are still increasing worldwide [8] [9] . It is believed that SARS-CoV-2 may persist among humans for a long time [10] , regardless of the availability of effective vaccines. Therefore, there is an urgent need to identify novel and efficient anti-COVID-19 drugs. SARS-CoV-2 belongs to the Coronaviridae family and is a positive-sense single-stranded RNA betacoronavirus [11, 12] [13] . In addition to SARS-CoV-2, six other human coronaviruses-HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, severe acute respiratory 1 These authors contributed equally to this work. syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV)-have been identified previously [14, 15] . HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1 usually only evoke mild cold-like symptoms [16, 17] ; hence, they are commonly used as drug screening tools for viral infectious diseases [18] . RNA-dependent RNA polymerase (RdRp), which mediates the transcription and replication of the RNA genome during infection, is a crucial enzyme in the life cycle of most RNA viruses, except retroviruses [19, 20] . The fact that this enzyme has no human counterpart, together with its essentiality for the life cycle of the virus, improves its potential as a drug target for antiviral development. Thus, this is a very active field of research and a hot topic for pharmaceutical companies and academic research groups [21] [22] [23] [24] [25] . A number of antiviral drugs, such as sofosbuvir, favipiravir, ribavirin, beclabuvir, and dasabuvir (Figure 1) , are in clinical use for different viruses (e.g., hepatitis C [26] [27] [28] , influenza [29] , and respiratory syncytial [30] viruses) on the basis of their anti-RdRp activity [31, 32] . Further, dozens of RdRp inhibitors are undergoing clinical trials, which were comprehensively summarized by Tian et al. in January 2021 [33] . In addition to the approved indications, most RdRp inhibitors have also been studied for the treatment of other viral infections [34] . In our previous work, we have reported a series of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides (Figure 2 ) as novel dual inhibitors of respiratory syncytial virus (RSV) and influenza A virus (IAV) with sub-micromolar EC 50 values; the mechanism study further suggested that these compounds act as RdRp inhibitors [35, 36] . Considering that the RdRp structure is highly conserved in RNA viruses, these compounds were evaluated for their SARS-CoV-2 RdRp inhibitory effect in a cell-based Gaussia luciferase (Gluc) reporter assay. Notably, most compounds showed moderate inhibitory activity (15%-40%) at a concentration of 10 µM; however, an increased inhibitory effect was observed when substituted aniline was replaced with benzylamine (6a1) or 2-methoxybenzylamine (6a5) ( Figure 2 ). Thus, a new series of 2-((indol-3-yl)thio)-N-benzyl-acetamides was synthesized and evaluated for its SARS-CoV-2 RdRp inhibitory effect in the Gluc reporter system. After a two-round optimization, compounds 6b2, 6b5, 6c9, 6d2, and 6d5 were identified as potent RdRp inhibitors with IC 50 values of 3.35 ± 0.21 µM, 4.55 ± 0.2 µM, 1.65 ± 0.05 µM, 3.76 ± 0.79 µM, and 1.11 ± 0.05 µM, respectively; the IC 50 of the positive control remdesivir was measured as 1.19 ± 0.36 µM. All the selected compounds 6b2, 6b5, 6c9, 6d2, and 6d5 showed dose-dependent inhibition of SARS-CoV-2 RdRp, and the activity was comparable to that of remdesivir. They inhibit the efficiency of SARS-CoV-2 RdRp-mediated RNA synthesis and diminish both plus-and minus-strand Gluc RNA level more potently than remdesivir. All the tested compounds showed good tolerance to nps14/nsp10 exoribonuclease, which is necessary for their efficacy in vivo. Finally, compound 6d5 was selected to evaluate its antiviral effect against HCoV-OC43 and HCoV-NL63; it was identified as the most potent candidate with a stronger inhibitory activity than remdesivir in vivo. The synthetic schemes for compounds 6a-d are illustrated in Scheme 1. Briefly, ethyl J o u r n a l P r e -p r o o f bromoacetate 1 was substituted with sodium thiosulfate to form the Bunte salt ethyl acetate-2-sodium thiosulfate 2, followed by substitution at the 3-position of indole (or substituted indole) and hydrolysis to yield a key intermediate 5. Finally, this intermediate was coupled with different substituted benzylamines to afford the target products 6a-d. Compound 6c9 was also generated via Suzuki-Miyaura cross-coupling of 6c8 with phenylboronic acid. All the target compounds were obtained in high purity (>95%) via separation using a flash column. They were fully characterized through NMR and high-resolution mass spectrometry. Details of the chemical synthesis and structural characterization can be found in the Materials and Experimental Details section. The 1 H and 13 C NMR spectra of 6a-d are presented in the supplementary material. Scheme 1. General synthetic scheme for compounds 6a-d. Reagents 2.1 Design, synthesis, and structure-activity relationshipesearch of compounds 6a1-6, 6b1-7, and 6c1-8 In our previous work, we discovered that 2-((1H-indol-3-yl)thio)-N-phenyl-acetamide specifically targets the RdRp of both RSV and IAV, resulting in replication inhibition at sub-micromolar EC 50 values [35, 36] . After the outbreak of COVID-19, we screened these compounds and found that several 2-((indol-3-yl)thio) acetamides moderately inhibited SARS-CoV-2 RdRp at 10 µM. When substituted aniline, at the right part of the molecule, was replaced with a benzylanine, increased potency of the compounds was observed (Figure 2) . Thus, a new series of 2-((indol-3-yl)thio)-N-benzyl-acetamides was designed. Compounds 6a1-6, 6b1-7, and 6c1-8 were prepared via the substitution of ethyl acetate-2-sodium thiosulfate with indole (or methyl-/bromo-substituted indole), followed by hydrolysis and coupling with a series of benzylamines. Subsequently, these compounds were tested for their SARS-CoV-2 RdRp inhibitory effect in a Gluc reporter system specifically initiated by the coronavirus RdRp, utilizing remdesivir as the positive control. The IC 50 values of compounds 6a1-6, 6b1-7, and 6c1-8 against SARS-COV-2 RdRp are listed in Table 1 . The cytotoxicity of these compounds was also tested under the same conditions. As shown in Table 1 , five out of the six compounds in the series 6a1-6 showed moderate SARS-CoV-2 RdRp inhibitory activity (45%-76%) at 10 µM, and the IC 50 value of the most potent compound 6a6 was measured to be 7.50 ± 1.68 µM. Compound 6a1 was the simplest in the series and showed moderate inhibitory activity. After the introduction of another benzyl group to the nitrogen atom in the amide, the RdRp inhibitory activity was enhanced, as shown by the IC 50 values of 6a1 (26.92 µM) vs. 6a2 (12.30 µM). However, after introducing an electron-withdrawing trifluoromethyl group at the 4-position of the benzyl ring, the activity was completely lost (6a3 vs. 6a1). The substitution with O-alkylated groups (e.g., methoxyl and dimethylaminoethoxy) or chlorine atom on the benzyl ring is also beneficial for the SARS-CoV-2 RdRp inhibitory effect (6a4-6 vs. 6a1). When the starting material N-methyl indole was replaced by indole, compounds in the series 6b1-7 were obtained. After the removal of the N-methyl group, the RdRp inhibitory activity significantly increased; compounds 6b1-2 were four times more potent than 6a1-2, as indicated by their IC 50 values. Similar to 6a3, 6b3 exhibited a significantly high inhibitory effect. These results indicate that the -NH-fragment is beneficial to their SARS-CoV-2 RdRp inhibitory activity, and this may be attributed to a hydrogen bond interaction between the ligand and receptor. Furthermore, the addition of another methyl or benzyl group at the nitrogen atom of amide slightly enhanced SARS-CoV-2 RdRp inhibitory activity, as indicated by the IC 50 values of 6b1 (6.81 µM) vs. 6b2 (3.31 µM) or 6b5 (4.55 µM). Meanwhile, a methyl group introduced to the methylene group of benzylamine caused negligible effects on SARS-CoV-2 RdRp inhibitory activity, as evidenced by the IC 50 values of 6b1 (6.81 µM) and 6b7 (6.68 µM). In our previous study [35] , we found that a bromine atom introduced on the indole ring can significantly increase the RdRp inhibitory effects of compounds in this series against IAV and RSV; thus, derivatives with a bromine substitution (6c1-8) were also designed and synthesized. All of these compounds exhibited potent inhibitory effects, and their IC 50 values were in the range of 4.55-10.72 µM. Among these brominated compounds, 6c1-2 and 6c7-8 displayed a more potent RdRp inhibitory activity than 6c3-6, suggesting that bromine substitution at position 4-or 7-is highly suitable for their interaction with RdRp. 2.2 Design, synthesis, and SAR research of compounds 6c9 and 6d1-5 To obtain highly efficacious SARS-CoV-2 RdRp inhibitors, compounds 6d1-5 were designed and synthesized using 4-/7-brominated indole and substituted benzylamine as the starting materials in the second-round optimization. Meanwhile, 6c9 was also synthesized to confirm whether another conjugation of benzene ring with indole benefits RdRp inhibition. After the synthesis of these derivatives, their SARS-CoV-2 RdRp inhibition activities were assayed as described above. As listed in Table 2 and depicted in Figure 3 , 6c9 shows significantly increased SARS-CoV-2 RdRp inhibitory activity (IC 50 = 1.65 ± 0.05 µM), indicating that it could act as a lead compound for the development of a novel SARS-CoV-2 RdRp inhibitor with high potency and improved drug-likeness properties. Derivatives 6d1-4 were designed based on the SAR obtained in the first-round optimization, and most of them exhibited good activities except 6d3. These results also proved that di-substitution on the amide nitrogen atom is beneficial for RdRp inhibition. To improve the drug-likeness properties of 6d1-2, another oxygen atom and ethyoxyl were introduced into the molecule and thus compound 6d5 was obtained. Notably, it was identified as the most potent SARS-CoV-2 RdRp inhibitor with an IC 50 value of 1.11 ± 0.05 µM and an acceptable log P value of 4.38. All data are expressed as mean ± SD of triplicate assays. a. Log P = Predicted octanol/water partition coefficient. The log P values were predicted using molinspiration (https://www.molinspiration.com/services/logp.html). b. The half-maximal cytotoxic concentration (CC 50 ) for each compound was calculated by comparing the viability of compounds-treated cells with that of DMSO-treated cells in cell countingkit-8 (CCK-8, Beyotime) assay. Figure 3 , all the selected compounds 6b2, 6b5, 6c9, 6d2, and 6d5 showed dose-dependent inhibition of SARS-CoV-2 RdRp, and the activity was comparable to that of remdesivir, as indicated by the IC 50 values. Compound 6d5 was identified as the most promising candidate with a lower IC 50 value than remdesivir and an excellent safety index. 2.3 Compounds 6b2, 6b5, 6c9, 6d2, and 6d5 inhibit RNA synthesis by SARS-CoV-2 RdRp After identifying the most potent SARS-CoV-2 RdRp inhibitors in the CoV-RdRp-Gluc reporter assay, we decided to evaluate whether they could also inhibit the efficiency of RNA synthesis by SARS-CoV-2 RdRp. Treatment with 5 µM and 10 µM of the compounds 6b2, 6b5, 6c9, 6d2, 6d5, or remdesivir decreased the levels of viral plus-and minus-strand Gluc RNA in a dose-dependent manner ( Figure 4A -F). Compounds 6b5, 6c9, and 6d5 diminished the levels of both plus-and minus-strand Gluc RNA more potently than the positive control (remdesivir). These data confirm that 6b2, 6b5, 6c9, 6d2, and 6d5 act as SARS-CoV-2 RdRp inhibitors. CoV-Gluc levels were determined via real-time qRT-PCR. Error bars indicate SD, **p<0.01, ***p<0.001. 2.4 6b2, 6b5, 6c9, 6d2, and 6d5 are resistant to proofreading activity of nsp14/nsp10 Coronavirus nonstructural protein 14 (nsp14) exoribonuclease in complex with its activator nonstructural protein 10 (nsp10) performs a proofreading function during coronavirus replication. It can excise erroneous mutagenic nucleotides incorporated by nsp12 into viral RNA. Ribavirin was reported to be excised from the nascent RNA strand of CoVs and showed limited efficacy in vivo [37] . To confirm whether compounds 6b2, 6b5, 6c9, 6d2, and 6d5 are resistant to the proofreading activity of exoribonuclease, we co-expressed nsp14 and nsp10 into the cell-based CoV-RdRp-Gluc system. Gluc activity of these compounds slightly declined in the presence of nsp14 and nsp10. All the compounds tested showed good tolerance of nps14/nsp10 with slightly increased IC 50 values ( Figure 5 and Table 3) , when compared with the data in Figure 4 . The IC 50 values for 6b2, 6b5, 6c9, 6d2, and 6d5 increased to a lesser extent than that of remdesivir, indicating that these compounds are more tolerant to CoV exoribonuclease. Compounds 6c9 and 6d5 were identified as the most promising inhibitors against SARS-CoV-2 RdRp; their IC 50 values were 2.18 µM and 1.89 µM, respectively, in the presence of nsp10/nsp14 exoribonuclease. In our previous study [38] , we suggested that nsp10/nsp14 exoribonuclease must be included in the cell-based CoV-RdRp-Gluc assay to identify effective RdRp inhibitors, as the exoribonuclease complex nsp14/nsp10 renders SARS-CoV-2 RdRp resistant to NA inhibitors. Ribavirin can be excised by exoribonuclease from the nascent RNA strand of CoVs to diminish its antiviral effect. Compounds 6b2, 6b5, 6c9, 6d2, and 6d5 showed better tolerance to nps14/nsp10 than remdesivir, indicating that these compounds may be more potent inhibitors of SARS-CoV-2 than remdesivir. Compound 6d5 was selected for evaluation of its antiviral effect against the human coronavirus strains HCoV-OC43 and HCoV-NL63, which are commonly used in antiviral drug screening, in a cell-based assay in vitro. The data in Figure 6 illustrate that replication of HCoV-OC43 and HCoV-NL63 was effectively inhibited in a dose-dependent manner after treatment with serially diluted 6d5. In particular, 6d5 showed a more potent inhibitory effect than remdesivir on HCoV-OC43 replication. Moreover, 6d5 exhibited a higher antiviral activity against HCoV-OC43 (which belongs to the same β-coronavirus as SARS-CoV-2) than against HCoV-NL63 (an α-coronavirus). According to serology studies and genomic analysis, coronavirus is divided into four genera: α-coronavirus, β-coronavirus, γ-coronavirus, and δ-coronavirus. HCoV-OC43 and SARS-CoV-2 are members of the β-coronavirus, whereas HCoV-NL63 is a member of the α-coronavirus. The higher antiviral activity of 6d5 against HCoV-OC43 than against HCoV-NL63 implies that this compound may act as a potent SARS-CoV-2 inhibitor. To explore the binding mode of identified inhibitors, molecular docking study of the most potent compound 6d5 against SARS-CoV-2 RdRp (PDB-ID: 6M7K) was performed using AutoDock Vina. As shown in Figure 7 , the binding pocket of 6d5 is located in the palm and finger subdomains of SARS-CoV-2 RdRp. The hydrogen on the indole nitrogen of 6d5 formed strong hydrogen bonds with Asp760, a highly conserved catalytic residue that is required for RNA synthesis. An H-bond interaction between the carbonyl oxygen atoms of 6d5 and Cys622 was also observed. Moreover, the benzene ring in 2-ethoxyaniline formed a π-cation and an edge-to-face π-π interaction with residues Arg553 and Try445, respectively. Dark blue, red, and green indicate positively charged, negatively charged, and hydrophobic residues, respectively. Hydrogen bonding is depicted as magenta arrows, π-cation interactions are depicted as red lines, and π-π interactions are depicted as green lines. To gain further insight into the structure-activity relationships of the 6d5 analogs, five 2-((1H-indol-3-yl)thio)-N-benzyl-acetamide derivatives (6a1, 6a2, 6b2, 6c7, and 6c9 ) that exhibited diverse inhibitory activities were also docked to SARS-CoV-2 RdRp. The calculated binding energies (DG ADV ) and predicted binding poses of these derivatives are depicted in Figure 8 and Figure 9 , respectively. The values of DG ADV were used to estimate the relative binding affinity of the inhibitors. As seen in Figure 8 , there is a positive linear relationship between DG ADV of selected derivatives and their corresponding experimental IC 50 values against SARS-CoV-2 RdRp (R 2 = 0.83), implying that the strong inhibitory effect of compounds is associated with their high binding affinity to SARS-CoV-2 RdRp. In addition, because of their common structural skeleton, it is reasonable to assume that the binding sites of these derivatives are similar to those of 6d5. As expected, all compounds presented a similar arrangement within the central cavity of SARS-CoV-2 RdRp (Figure 9A) . As the simplest compound in the series, 6a1 showed a moderate binding energy (-5.0 kcal/mol). After the introduction of another benzyl group to the nitrogen atom in the amide, a more favorable binding energy was obtained for 6a2 (-6.1 kcal/mol). Although the H-bond interactions were lost, the benzene ring of 6a2 contributed to additional hydrophobic interactions with Phe793 and Met794. Additionally, strong π-cation interactions were observed between 6a2 and Arg553. These observations may explain why 6a2 had a stronger inhibitory effect than 6a1. Comparison of 6b2 and 6a2. The calculated binding energy of 6b2 was -7.1 kcal/mol, which is more favorable than that of 6a2. The only structural difference between 6a2 and 6b2 is the substituent at the nitrogen atom of indole. As seen in Figure 9C , there is an additional H-bond between the -NH-fragment in the indole ring and the carboxyl group of Asp623 and may account for the stronger inhibitory activity of 6b2 (IC 50 = 3.35 µM) than that of 6a2. Comparison of 6c7 and 6c9. The only structural difference between 6c7 and 6c9 is the substituent on the benzene ring of indole. When the bromine atom in 6c7 was replaced with a benzene ring, additional hydrophobic interactions were formed between 6c9 and palm subdomain residues Try800, Phe812, and Cys813. Consequently, 6c9 exhibited more favorable binding energy (-7.2 kcal/mol) than 6c7 (-6.1 kcal/mol). Thus, we speculated that the introduction of a benzene ring at this position improves the inhibitory effect of the compounds. negatively charged, polar, and hydrophobic residues, respectively. Hydrogen bonding is depicted as magenta arrows, π-cation interactions are depicted as red lines, and π-π interactions are depicted as green lines. RdRp is a crucial enzyme in the life cycle of most RNA viruses. Considering that this enzyme has no human counterpart and that it is essential for the life cycle of viruses, it a popular therapeutic drug target pursued by pharmaceutical companies and academic research groups. RdRp is considered a conserved protein within RNA viruses; thus, scientists worldwide have repurposed preexisting drugs that target RdRp to identify candidates against SARS-CoV-2. In this paper, we report the discovery of SARS-CoV-2 RdRp inhibitors based on the structural optimization of the IAV and RSV RdRp ligands. After a two-round optimization, compounds 6b2, 6b5, 6c9, 6d2, and 6d5 were identified as potent RdRp inhibitors with IC 50 values of 3.35 ± 0.21 µM, 4.55 ± 0.2 µM, 1.65 ± 0.05 µM, 3.76 ± 0.79 µM, and 1.11 ± 0.05 µM, respectively, whereas the IC 50 of remdesivir (control) was measured as 1.19 ± 0.36 µM. Compound 6d5 was identified as the most potent candidate, having a more potent inhibitory activity than remdesivir against HCoV-OC43 in a cell-based assay. Molecular docking studies were carried out to explore the binding mode and structure-activity relationships of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamide derivatives. As seen in Figure 7A and Figure 9A , the predicted binding sites of these inhibitors were located at the palm and finger subdomains of SARS-CoV-2 RdRp. Specifically, these active compounds interact with motif A residues D618-R624, palm domain residues K794, S795, D760, and D761, and finger domain residues D452, Y455, K551, and R553. Given that D618, D760, and D761 are involved in binding two magnesium ions at the catalytic center, the binding of these compounds may block the conformational change required to coordinate the divalent cations during the catalytic process. Notably, the strong correlation between the calculated binding energies and experimental IC 50 values implies that the strong inhibitory effect of compounds is associated with their high binding affinity to SARS-CoV-2 RdRp. Structure-activity relationship analysis highlighted that the -NHfragment in the indole ring makes an important contribution to the binding of RdRp through a hydrogen bond and that an additional aromatic ring on the indole ring or the nitrogen in amide is beneficial for the ligand-receptor interaction. We often believe that drugs should be of nanomolar potency in medicinal chemistry, and most approved drugs comply with this "nanomolar rule"; however, there are a few exceptions such as sofosbuvir, favipiravir, and ribavirin. Thus, further structural optimization for the improvement of the activity is underway. The current work is a successful attempt to identify new anti-SARS-CoV-2 candidates from other viral RdRp inhibitors. In summary, a new series of 2-((indol-3-yl)thio)-N-benzyl-acetamides was designed and synthesized based on the screening results of our antiviral library and a two-round optimization, and 6b2, 6b5, 6c9, 6d2, and 6d5 were identified as potent SARS-CoV-2 RdRp inhibitors. They can inhibit the efficiency of RNA synthesis by SARS-CoV-2 RdRp and diminish the level of both plus-and minus-strand Gluc RNA more potently than the positive control remdesivir. The most potent compound 6d5 showed stronger inhibitory activity than remdesivir against HCoV-OC43 in cells and has been selected as a potential candidate for further investigation. All starting materials for chemical synthesis were purchased from commercial suppliers (Shanghai Bide Pharmaceutical Technology Co., Ltd. & Beijing InnoChem Science & Technology Co., Ltd) and used without further purification. NMR spectra were recorded on Bruker Avance 400 MHz and 500 MHz spectrometers. LC-MS and purity data were measured using an Agilent HPLC/MSD instrument. APCI high-resolution mass spectra (HRMS) were recorded on an Autospec Ultima-TOF spectrometer. Sodium S- (2- General procedure for the synthesis of 6a1-6, 6b1-7, 6c1-8, 6d1-5, and 6c9 To a solution of compound 5 in dichloromethane (0.2 mmol/mL) was added DIEA (2.4 eq.), HATU (2.2 eq.) and substituted benzyl amine (1.1eq.). The solution was stirred for 1h at 25 °C and diluted with dichloromethane and washed with 30 mL of saturated sodium bicarbonate, sodium bicarbonate, 0.5N hydrochloric acid and saturated sodium chloride solution in sequence. After purification on a silica column (PE/EA=10:1 ~ 5:1) the target product was afforded. Purity: 95.7%. J o u r n a l P r e -p r o o f Hz, 2H), 3.75 (s, 3H), 3.36 (s, 2H). 13 Purity: 96.0%. 1 Purity: 97.9%. 1 Purity: 99.5%. 1 Purity: 97. The codon-optimized pCOVID19-nsp12, pCOVID19-nsp7, pCOVID19-nsp8, pCOVID19-nsp10 and pCOVID19-nsp14 was encoding a flag-tagged nsp12, nsp7, nsp8, nsp10 and nsp14 at its C-terminus, HCoV-NL63 at an MOI 0.01. After incubated in 2% FBS and each of test compounds for 120 hours at 33 °C in 5% CO 2 incubator, 20 µL of MTS Cell Proliferation Colorimetric reagent was added into each well and incubated for another 3 hours at 37 ℃. The absorbance at 490 nm was measured using the Enspire 2300 Multiable reader (PekinElmer). Data are presented as the means ± SD from at least three independent experiments and statistical analyses were performed using a two-tailed Student's t-test. Differences between groups were considered statistically significant if p < 0.01(**), p < 0.001(***) The cryo-electron microscopy structure of SARS-CoV-2 RdRp (PBD ID: 6M71) was prepared for docking using AutoDockTools (ADT, version: 1.5.6) by removing co-crystalized water molecules, adding polar hydrogens, and merging Gasteiger charges. The active site of SARS-CoV-2 RdRp was defined as a box of 26 Å×26 Å×26 Å, centered near the active sites (x=123.6 Å, y=117.84 Å, z=133.6 J o u r n a l P r e -p r o o f Å). For each compound, we sampled the torsion angles of all rotatable bonds to generate multiple conformations. Each conformation was then assigned hydrogen appropriate for pH 7.4 and converted to PDBQT format input file using Open Babel (version 2.3.2). Molecular docking study was performed by using Auto Dock Vina software as previously described [41] . The final docked structure with the best binding energy (∆G ADV ) was selected for each compound. The protein-ligand interactions were visually inspected by using PyMOL (version 2.3.4) and Free Maestro (version 11.8.012). The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 400 MHz, DMSO-d 6 ) δ 11.52 (s, 1H), 8.17 (t, J = 5.9 Hz, 1H), 7.61 (dd, J = 1.8, 0.5 Hz, 1H), 7.58 -7.53 (m, 1H), 7.50 (d, J = 2.6 Hz, 1H) Hz, 1H), 7.57 -7.48 (m, 3H), 7.38 (d, J = 2.0 Hz, 1H) HRMS (ESI) m/z calcd. for C 17 H 13 BrCl 2 N 2 OSNa 400 MHz, DMSO-d 6 ) δ 11.69 -11.63 (m, 1H), 8.17 (t, J = 5.9 Hz, 1H), 7.66 -7.59 (m, 1H), 7.53 (dd, J = 2.8, 1.0 Hz, 1H), 7.38 (dd, J = 7.6, 0.8 Hz, 1H) DMSO-d 6 ) δ 11.69 -11.64 (m, 1H) Hz, 1H), 7.54 (d, J = 2.7 Hz, 1H), 7.49 (d, J = 8.3 Hz, 1H), 7.41 -7.34 (m, 2H) -bromo-1H-indol-3-yl)thio)-N-methylacetamide 6d1 400 MHz, DMSO-d 6 ) δ 11.73 (s, 1H), 7.59 (minor) + 7.53 (major) (d, J = 2.7 Hz, 1H) J = 8.1, 0.9 Hz, 1H), 7.33 (m, 2H), 7.29 -7.22 (m, 2H) Rotamers formed because of tertiary amides in the structure which was similar to that reported in literature -bromo-1H-indol-3-yl)thio)acetamide 6d2 77 (s, 2H). 13 C NMR (101 MHz, DMSO-d 6 ) HRMS (ESI) m/z calcd. for C 24 H 21 BrN 2 OSNa -bromo-1H-indol-3-yl)thio)-N-methylacetamide 6d3 400 MHz, DMSO-d 6 ) δ 11.68 (s, 1H), 7.66 -7.52 (m, 2H), 7.38 (td, J = 7.1, 6.6, 0.9 Hz, 1H), 7.35 -7.29 (m, 2H), 7.29 -7.22 (m, 1H), 7.19 -7.09 (m, 2H) Rotamers formed because of tertiary amides in the structure which was similar to that reported in literature -bromo-1H-indol-3-yl)thio)acetamide 6d4 DMSO-d 6 ) δ 11.68 (d, J = 2 Hz, 1H), 7.34 -7.22 (m, 6H), 7.15 -7.11 (m, 2H), 7.10 -7.06 (m, 2H), 7.01 (t, J = 7.7 Hz, 1H) -ethoxybenzyl)-2-((4-bromo-1H-indol-3-yl)thio)-N-methoxyacetamide 6d5 12 -6.99 (m, 2H), 6.96 (dd, J = 8.3, 1.0 Hz, 1H), 6.87 (td, J = 7.5, 1.1 Hz, 1H), 4.02 (q, J = 6.9 Hz, 2H), 3.75 (s, 2H), 3.57 (s, 3H), 1.32 (t, J = 6.8 Hz, 3H). 13 C NMR (101 MHz, DMSO-d 6 ) Pd 2 (dba) 3 (18mg, 0.02 mmol.), SPhps (16mg, 0.04 mmol.) and Cs 2 CO 3 (651mg, 2mmol) were dissolved in 1,4-dioxane (2 mL) under Ar. The mixture was stirred for 3h at 125 °C in a CEM microwave reactor 400 MHz, DMSO-d 6 ) δ 11.29 (d, J = 2.8 Hz, 1H), 8.21 (t, J = 5.9 Hz, 1H), 7.68 -7.59 (m, 3H), 7.57 -7.49 (m, 2H), 7.48 -7.41 (m, 2H), 7.25 -7.15 (m, 3H) ) supplemented with 10% (v/v) fetal bovine serum (FBS; Gibco). Cells were cultured at 37°C in the incubator supplied with 5% of CO 2 Plasmid were transfected using the VigoFect transfection reagent (Beijing Vigorous, Beijing, China) according to the manufacturer's instructions. HCT-8 cells were World Health Organization, WHO Coronavirus (COVID-19) Dashboard Remdesivir for the Treatment of Covid-19 -Final Report Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial Remdesivir in adults with severe COVID-19: a randomised, double-blind Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Remdesivir and interferon fall flat in WHO's megastudy of COVID-19 treatments World Health Organization, WHO Coronavirus (COVID-19) Dashboard Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period Characteristics of SARS-CoV-2 and COVID-19 Coronavirus biology and replication: implications for SARS-CoV-2 Features, Evaluation, and Treatment of Coronavirus (COVID-19) Chapter Four -Structural insights into coronavirus entry Genotype and phenotype of COVID-19: Their roles in pathogenesis Chapter Eight -Hosts and Sources of Endemic Human Coronaviruses Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae), Encyclopedia of Virology Safe and Sensitive Antiviral Screening Platform Based on Recombinant Human Coronavirus OC43 Expressing the Luciferase Reporter Gene A Structural Overview of RNA-Dependent RNA Polymerases from the Flaviviridae Family RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2 Targeting the RdRp of Emerging RNA Viruses: The J o u r n a l P r e Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2 Non-nucleoside Inhibitors of Zika Virus RNA-Dependent RNA Polymerase SARS-CoV-2 RNA Dependent RNA polymerase (RdRp)-A drug repurposing study Hepatitis C: A Pharmacological Therapeutic Update Beclabuvir for the treatment of hepatitis C Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase Respiratory syncytial virus: diagnosis, prevention and management Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting viruses RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic Potential use of RNA-dependent RNA polymerase (RdRp) inhibitors against SARS-CoV2 infection Design and synthesis of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides as novel dual inhibitors of respiratory syncytial virus and influenza virus A Synthesis and Biological Evaluation of Substituted Indole and Its Analogs as Influenza A Virus Inhibitors Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase Rotamers or diastereomers? An overlooked NMR solution NMR strategies to support medicinal chemistry workflows for J o u r n a l P r e -p r o o f primary structure determination Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase